<?xml version="1.0" encoding="UTF-8"?>
<p>Antioxidants in diet and supplements are widely used to protect cells from the damage induced by ROS. However, some clinical trials have shown conflicting results that do not support this concept. Based on recent studies, antioxidants may increase melanoma metastasis in mice [
 <xref rid="B21-molecules-25-04207" ref-type="bibr">21</xref>,
 <xref rid="B22-molecules-25-04207" ref-type="bibr">22</xref>] and accelerate tumor progression in later stages of lung cancer [
 <xref rid="B23-molecules-25-04207" ref-type="bibr">23</xref>]. One explanation of the antioxidant activity in promoting tumor growth is the disruption of the ROS-p53 axis, which is related to the somatic mutation in p53 that occurred in the late stage of tumor progression [
 <xref rid="B23-molecules-25-04207" ref-type="bibr">23</xref>]. In fact, mutant p53 isoforms cannot apply antioxidant activities, and rather induce intracellular ROS and promote a pro-tumorigenic survival [
 <xref rid="B24-molecules-25-04207" ref-type="bibr">24</xref>]. Interestingly, the administration of mitochondria and non-mitochondria-targeted antioxidants resulted in two distinguished outcomes of liver cancer prevention by altering DNA repair [
 <xref rid="B25-molecules-25-04207" ref-type="bibr">25</xref>]. 
 <xref ref-type="fig" rid="molecules-25-04207-f001">Figure 1</xref> describes the role of oxidative stress in cancer.
</p>
